Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent
Compounds that activate SERCA2a may lead to novel therapies for heart failure WARRINGTON, Pa. , April 17, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular
Article Date
April 17, 2023
This article is featured on another website.
Go to article
May 13, 2025
Myrtelle to Present Breakthrough Insights at ASGCT 2025 New Orleans
The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.
May 13, 2025
Myrtelle to Present Breakthrough Insights at ASGCT 2025 New Orleans
The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.